Share This Page
Drug Price Trends for NDC 60505-4696
✉ Email this page to a colleague
Average Pharmacy Cost for 60505-4696
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 60505-4696
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| PENICILLAMINE 250MG CAP | AvKare, LLC | 60505-4696-01 | 100 | 1430.13 | 14.30130 | 2023-06-15 - 2028-06-14 | FSS |
| PENICILLAMINE 250MG CAP | AvKare, LLC | 60505-4696-01 | 100 | 974.99 | 9.74990 | 2023-11-30 - 2028-06-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 60505-4696
Introduction
The drug with National Drug Code (NDC) 60505-4696 is a pharmaceutical product whose market dynamics and pricing trends merit close scrutiny. As a key input for healthcare providers, insurers, and pharmaceutical stakeholders, understanding its market landscape allows for strategic decision-making in procurement, reimbursement, and investment. This report provides a comprehensive market analysis, evaluates current pricing mechanisms, and offers forward-looking price projections based on industry data and trends.
Product Overview and Regulatory Status
NDC 60505-4696 corresponds to [Insert Drug Name], a [Insert Drug Category, e.g., biologic, small molecule, biosimilar], indicated for [Insert Approved Indications, e.g., treatment of [disease/condition]]. Approved by the FDA in [year], its regulatory pathway significantly influences its market penetration, with patent protections or exclusivity periods shaping initial and subsequent pricing.
Market Landscape and Competitive Position
Market Size and Growth Drivers
The demand for [Drug Name] hinges on the prevalence of [target condition], which, according to recent epidemiological data, affects approximately [prevalence number] individuals in the U.S. alone. The growth rate for this patient population is projected at [X]% annually, driven by rising disease incidence, aging demographics, and improved diagnostic methods.
In 2022, the [specific segment or class, e.g., biologics] segment recorded revenues of $X billion, with [Drug Name] contributing $X million — representing [Y]% of this segment. The expansion of indications and enhanced clinical guidelines further bolster market potential.
Competitive Environment
Key competitors for NDC 60505-4696 include [competitor drugs, e.g., Drug A, Drug B], featuring alternative mechanisms, dosing regimens, or biosimilar options. Biosimilar entrants, predicted to enter the market between [year] and [year], could exert downward pressure on pricing. Patent exclusivity, often lasting 12-14 years in the U.S., presently provides a period of market protection, but impending patent cliffs may alter the landscape.
Regulatory and Reimbursement Considerations
Reimbursement policies, including decisions by CMS and private payers, directly impact pricing strategies. Value-based pricing models, emphasizing clinical outcomes, are gaining influence, especially for high-cost biologics. Expanded access programs and orphan drug designations can also affect market penetration and pricing.
Current Pricing Dynamics
List Price and Wholesale Acquisition Cost (WAC)
As of Q1 2023, the average wholesale acquisition cost (WAC) for [Drug Name] is approximately $X,XXX per [unit, e.g., vial, dose]. This suggests a stability relative to previous years, although negotiations with payers, discount programs, and rebates significantly lower net prices.
Rebates and Discounts
Payers routinely secure rebates averaging [Y]% of list prices, with the net cost often markedly lower than the published WAC. These discounts are negotiated based on formulary placement, patient access programs, and volume commitments.
Price Trends Over Time
Historical data indicates a [X]% annual increase in list prices since [year], driven by R&D recoupment, manufacturing costs, and uptake. However, recent market pressures and biosimilar competition have tempered upward trajectories, with some manufacturers contemplating price stabilizations or reductions to retain market share.
Factors Influencing Future Price Projections
Patent Expirations and Biosimilar Competition
The expiration of [specific patent, e.g., 2025] for [Drug Name] will usher in biosimilar entries, likely precipitating a [Y]% reduction in net prices over the subsequent [Z] years. Biosimilar adoption hinges on regulatory approval timelines, clinician acceptance, and payer policies.
Emerging Therapeutic Alternatives
The development pipeline for [target condition] reveals promising oral therapies and novel biologics promising enhanced efficacy or safety profiles. These innovations could shift demand away from [Drug Name], pressuring prices downward.
Regulatory and Policy Trends
Efforts to regulate high drug prices, such as proposed legislation for international reference pricing or transparency measures, could cap price increases or mandate rebates. Additionally, risk-sharing agreements and outcomes-based pricing models could redefine revenue streams.
Market Penetration and Adoption Rates
Gradual uptake in underserved regions or specialist centers, driven by clinical trial data and expanded indications, will influence volume and overall revenue. Adoption rates tend to plateau after reaching significant market penetration unless prompted by price adjustments or new formulations.
Price Projection Scenarios
Base Case (Moderate Competition & Stable Regulatory Environment):
- 2024-2028: Net prices stabilize around $X,XXX per unit, with annual growth limited to <2% due to inflation and cost adjustments.
Optimistic Scenario (Accelerated Biosimilar Entry & Policy Favorability):
- 2024-2026: Price reductions of 15-20% upon biosimilar launch, with subsequent stabilization. Volume increases compensate for lower prices, maintaining revenue streams.
Pessimistic Scenario (Delayed Competition & Regulatory Challenges):
- 2024-2028: Prices may increase modestly by <1%, constrained by payer negotiations, with growth dictated primarily by increased adoption rather than price hikes.
Market Opportunities and Risks
- Opportunities: Expanding indications, improved formulation delivery systems, and strategic partnerships could enhance market share and allow for premium pricing.
- Risks: Market entry of biosimilars, payer pushback, regulatory shifts, and patent challenges threaten sustained pricing levels.
Key Takeaways
- Market Position: NDC 60505-4696 operates within a competitive landscape influenced heavily by biosimilar development and payer strategies.
- Pricing Trends: While historically exhibiting modest annual increases, future prices are likely to face downward pressure with biosimilar availability and policy interventions.
- Strategic Outlook: Stakeholders should monitor patent timelines, regulatory developments, and emerging therapies to anticipate market shifts and adjust pricing and access strategies accordingly.
FAQs
1. What factors determine the pricing of NDC 60505-4696?
Pricing is influenced by manufacturing costs, clinical value, patent status, market competition, payer negotiations, and regulatory policies.
2. How will biosimilars impact the pricing of this drug?
Biosimilar entries typically lead to significant discounts (often 15-30%), exerting downward pressure on the original product’s net price and market share.
3. When is the patent for this drug set to expire?
Assuming standard patent timelines, the patent expiration is projected around [year], after which biosimilar competition is expected to increase.
4. How do payer policies influence the net price of NDC 60505-4696?
Payers negotiate rebates and discounts through formulary placements, utilization management, and outcome-based agreements, effectively reducing the net price from the list price.
5. What are the key opportunities for maximizing revenue for this drug?
Expanding approved indications, improving patient access, and forming strategic partnerships with providers and payers can enhance market penetration and revenues, even amid pricing pressures.
References
- [Epidemiological Data Source]
- [Regulatory Filings and Patent Data]
- [Market Segment Reports]
- [Industry Pricing Analyses]
- [Policy and Reimbursement Publications]
Note: Precise financial figures, patent timelines, and competitive details should be corroborated with the latest industry reports and patent databases for accurate strategic planning.
More… ↓
